Efficacy of Pembrolizumab in the Treatment of Advanced Colorectal Cancer
Keywords:
Abstract
Colorectal cancer continues to be one of the leading causes of mortality among patients with neoplasia worldwide, just behind to breast and prostate cancer. The aim of this study was to evaluate the efficacy of pembrolizumab in advanced colorectal neoplasms, to offer patients greater survival. A search for scientific papers was carried out on the Pubmed and Lilacs platforms, using the following descriptors "colorectal cancer", "pembrolizumab" and "efficacy", both in Portuguese and in English, both being connected by the Boolean descriptor "AND". Thus, a total of 33 articles were included after inclusion and exclusion criteria. Despite the progress of studies, these lines of treatment are limited to patients due to the high cost of medications.
Downloads
How to Cite
References
Alice Shin, Filippo Giancotti, Anil Rustgi (2023) Metastatic colorectal cancer: mechanisms and emerging therapeutics. 44(4), 222-236.
Inés Mármol, Cristina Sánchez-De-Diego, Alberto Pradilla Dieste, Elena Cerrada, María Rodriguez Yoldi (2017) Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. 18(1), 197.
Thierry André, Kai-Keen Shiu, Tae Kim, Benny Jensen, Lars Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna Bendell, Dung Le, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Farooqui, Patricia Marinello, Luis Diaz (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. 383(23), 2207-2218.
Karuna Ganesh, Zsofia Stadler, Andrea Cercek, Robin Mendelsohn, Jinru Shia, Neil Segal, Luis Diaz (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. 16(6), 361-375.
Ahui Fan, Boda Wang, Xin Wang, Yongzhan Nie, Daiming Fan, Xiaodi Zhao, Yuanyuan Lu (2021) Immunotherapy in colorectal cancer: current achievements and future perspective. 17(14), 3837-3849.
Xuan Zhang, Tao Wu, Xinyi Cai, Jianhua Dong, Cuifeng Xia, Yongchun Zhou, Rong Ding, Renfang Yang, Jing Tan, Lijuan Zhang, Ya Zhang, Yuqin Wang, Chao Dong, Yunfeng Li (2022) Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. 13, 795972.
Emilie Picard, Chris Verschoor, Grace Ma, Graham Pawelec (2020) Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. 11, 369.
Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang, Xinxiang Li (2022) Exploring immunotherapy in colorectal cancer. 15(1), 95.
Gerardo Rosati, Giuseppe Aprile, Alfredo Colombo, Stefano Cordio, Marianna Giampaglia, Alessandro Cappetta, Concetta Porretto, Alfonso De Stefano, Domenico Bilancia, Antonio Avallone (2022) Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. 10(5), 1035.
Jiahao Zhu, Jie Lian, Benjie Xu, Xiangyi Pang, Shengjun Ji, Yutian Zhao, Haibo Lu (2023) Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. 14, 1120684.
Marc Roth, Satya Das (2021) Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. 21(2), 229-238.
Salomon Manz, Marco Losa, Ralph Fritsch, Michael Scharl (2021) Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. 14, 17562848211002018.
Thierry André, Filippo Pietrantonio, Antonio Avallone, Mahmut Gumus, Lucjan Wyrwicz, Jong Kim, Suayib Yalcin, Mariusz Kwiatkowski, Sara Lonardi, Jakub Zolnierek, Amos Odeleye-Ajakaye, Pierre Leconte, David Fogelman, Tae Kim (2023) KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer. 19(37), 2445-2452.
Tobias Justesen, Ismail Gögenur, Line Tarpgaard, Per Pfeiffer, Camilla Qvortrup (2023) Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol. 13(6), e073372.
Brigida Maiorano, Alessandro Parisi, Evaristo Maiello, Davide Ciardiello (2022) The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. 12(10), 1552.
Prashanth Rawla, Adam Barsouk, Andreas Hadjinicolaou, Alexander Barsouk (2019) Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. 7(8), 83.
Baptiste Cervantes, Thierry André, Romain Cohen (2024) Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. 16, 17588359231170473.
Chaoyuan Kuang, Yongseok Park, Ryan Augustin, Yan Lin, Douglas Hartman, Lindsey Seigh, Reetesh Pai, Weijing Sun, Nathan Bahary, James Ohr, John Rhee, Stanley Marks, H Beasley, Yongli Shuai, James Herman, Hassane Zarour, Edward Chu, James Lee, Anuradha Krishnamurthy (2022) Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. 14(1), 3.
Sean Ronnekleiv-Kelly, Richard Burkhart, Timothy Pawlik (2016) Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. 25(3), 190-199.
Yuji Miyamoto, Katsuhiro Ogawa, Mayuko Ohuchi, Ryuma Tokunaga, Hideo Baba (2022) Emerging evidence of immunotherapy for colorectal cancer. 7(2), 216-224.
Xiang Chen, Ling-Juan Chen, Xiao-Fei Peng, Ling Deng, Yan Wang, Jiu-Jiang Li, Dong-Li Guo, Xiao-Hua Niu (2024) Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. 40, 101851.
Chongkai Wang, Dawnyel Chevalier, Janelle Saluja, Jaideep Sandhu, Cecilia Lau, Marwan Fakih (2020) Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. 25(8), e1188-e1194.
Luca Cancanelli, Melania Rivano, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato, Andrea Messori (2021) Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. 13(11), e19893.
Xiao Zhang, Zhengyang Yang, Yongbo An, Yishan Liu, Qi Wei, Fengming Xu, Hongwei Yao, Zhongtao Zhang (2022) Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. 20(1), 93.
Gerhard Jung, Daniel Benítez-Ribas, Ariadna Sánchez, Francesc Balaguer (2020) Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update. 9(11), 3520.
Christos Fountzilas, David Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna Rosenheck, Erik Knudsen, Jason Muhitch, Scott Abrams, Chong Wang, Alan Hutson, Kristopher Attwood, Karen Hicks, Jennifer Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick Boland (2021) Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. 27(24), 6726-6736.
M Morse, H Hochster, A Benson (2020) Perspectivas no tratamento do câncer colorretal metastático com terapia inibidora de checkpoint imune. 25(1), 33-45.
Albiruni Razak, James Cleary, Victor Moreno, Michael Boyer, Emiliano Calvo Aller, William Edenfield, Jeanne Tie, R Harvey, Annemie Rutten, Manish Shah, Anthony Olszanski, Dirk Jäger, Nehal Lakhani, David Ryan, Erik Rasmussen, Gloria Juan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit, Dirk Nagorsen, Kyriakos Papadopoulos (2020) Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. 8(2), e001006.
Dae Kim, Elaine Tan, Jun-Min Zhou, Michael Schell, Maria Martinez, James Yu, Estrella Carballido, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Richard Kim (2021) A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. 124(11), 1803-1808.
Elena Elez, Scott Kopetz, Josep Tabernero, Tanios Bekaii-Saab, Julien Taieb, Takayuki Yoshino, Gulam Manji, Kathrine Fernandez, Antonello Abbattista, Xiaosong Zhang, Van Morris (2023) SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. 20(11), 653-663.
Chongkai Wang, Jaideep Sandhu, Marwan Fakih (2019) Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. 10(1), 161-165.
Osama Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew Brohl, Philippe Bedard, Daniel Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F Stephen Hodi (2022) Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. 10(3), e003569.
T Água Doce, A Kondic, M Ahamadi, C Li, R De Greef, D De Alwis, J Pedra (2017) Avaliação da estratégia de dosagem de pembrolizumabe para indicações oncológicas. 16, 43.
Henry Smith, Anne Bodilsen, Lisbeth Rose, Rahim Altaf, Lene Iversen, Line Walker (2023) Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report. 106, 108286.
L Pereira, F Nunes, P Santos (2018) Biomarcadores preditivos em imuno-oncologia. Oncologia: da prevenção ao tratamento. 39(2), 485-501.
Published
2024-09-21
Issue
Section
License
Copyright (c) 2024 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.